NetworkNewsBreaks – InMed Pharmaceuticals Inc. (
Post# of 228
(Total Views: 309)
Posted On: 06/14/2022 3:47:35 PM
NetworkNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Results of Peer-Reviewed Study Published in International Journal
InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, has had its peer-reviewed scientific study published in the “International Journal of Molecular Sciences.” Titled “Effects of Rare Phytocannabinoids on the Endocannabinoid System of Human Keratinocytes,” the article reports on the study’s efforts to examine the biological activity of tetrahydrocannabivarin (“THCV”), cannabichromene (“CBC”) and other rare cannabinoids as well as the potential these substances have in addressing various skin conditions. The study used a recognized in vitro model of human keratinocytes to analyze how specific cannabinoids interacted with cannabinoid receptors and other endocannabinoid system components; the results indicate that each cannabinoid had distinct biological activity via the endocannabinoid system. The study was conducted in collaboration with Dr. Mauro Maccarrone, professor and chair of biochemistry at the Department of Biotechnological and Applied Clinical Sciences at the University of L’Aquila in Italy. “This peer-reviewed study provides important scientific research investigating the distinctly different physiological effects of rare cannabinoids,” said InMed Pharmaceuticals senior VP of preclinical research and development Dr. Eric Hsu in the press release. “As we continue to expand our portfolio of rare cannabinoids, including THCV and CBC, evidence-based research is imperative to improving our understanding of their biological activity. There is growing interest in the potential benefits of rare cannabinoids and this study represents InMed’s commitment to contributing to the body of research of rare cannabinoids.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, has had its peer-reviewed scientific study published in the “International Journal of Molecular Sciences.” Titled “Effects of Rare Phytocannabinoids on the Endocannabinoid System of Human Keratinocytes,” the article reports on the study’s efforts to examine the biological activity of tetrahydrocannabivarin (“THCV”), cannabichromene (“CBC”) and other rare cannabinoids as well as the potential these substances have in addressing various skin conditions. The study used a recognized in vitro model of human keratinocytes to analyze how specific cannabinoids interacted with cannabinoid receptors and other endocannabinoid system components; the results indicate that each cannabinoid had distinct biological activity via the endocannabinoid system. The study was conducted in collaboration with Dr. Mauro Maccarrone, professor and chair of biochemistry at the Department of Biotechnological and Applied Clinical Sciences at the University of L’Aquila in Italy. “This peer-reviewed study provides important scientific research investigating the distinctly different physiological effects of rare cannabinoids,” said InMed Pharmaceuticals senior VP of preclinical research and development Dr. Eric Hsu in the press release. “As we continue to expand our portfolio of rare cannabinoids, including THCV and CBC, evidence-based research is imperative to improving our understanding of their biological activity. There is growing interest in the potential benefits of rare cannabinoids and this study represents InMed’s commitment to contributing to the body of research of rare cannabinoids.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)InMed Pharmaceuticals, Inc. (INM) Stock Research Links
Scroll down for more posts ▼